Immune cells become potent cancer killers after genetic redirection

Scientists have made significant progress towards understanding how the immune system can be more specifically and efficiently targeted against cancer cells. The research, published in the January issue of Immunity, may provide the basis for development of a new, extensive immunotherapy for human tumors.

Normal cells that have transformed into cancer cells produce and display large amounts of proteins called tumor- and leukemia-associated antigens (TAA). Although immune cells recognize TAAs it has been difficult to develop immunotherapies for humans based on these interactions, in part because many normal cells and tissues produce small amounts of TAAs and the body has a certain amount of self-tolerance that prevents a vigorous immune attack.

Dr. Matthias Theobald from Johannes Gutenburg-University in Mainz, Germany, and colleagues used sophisticated genetic techniques to circumvent this self-tolerance and essentially redirect key human immune cells. Specifically, the researchers focused on the p53 tumor suppressor protein that is mutated in the majority of human cancers. Immune self-tolerance to p53 exists because of low levels of wild-type p53 that are expressed by normal cells.

The researchers used special mice genetically engineered that lack the normal action of CD8 cells required for development of self-tolerance to generate an immune cell receptor (TCR) specific for tumor-associated p53. The gene for this receptor was then transferred to human immune cells and resulted in redirected CD4+ Th and CTL immune cells that aggressively attacked tumor cells.

According to Dr. Theobald, "Our study on the intentional redirection of human CD4+ Th cells and high-avidity CD8 CTL by the delivery of genes encoding a single CD8-independent, high-affinity p53A2.1-specific TCR lays the foundation for the exploitation of this approach for a novel, broad-spectrum immunotherapy of malignant disease."


Contact: Heidi Hardman
Cell Press

Page: 1

Related biology news :

1. Immune system escape hatch gives cancer cells traction
2. Immune antibodies penetrate neurons to clear Alzheimers-linked amyloid
3. Immune response to cancer stem cells may dictate cancers course
4. Immune systems in breast cancer survivors who suffer from fatigue fail to shut off after therapy
5. Immune response to HIV in the brain
6. Immune substances may help antibody-based drugs fight cancer
7. Immune cell receptors act in combination to regulate attack
8. Immune system has evolved to prevent autoimmune disease
9. Immune cells known as macrophages linked to growth of lymph vessels in eyes, scientists discover
10. Immune systems distress signal tells bacteria when to strike back
11. Immune cells genetic jam session is controlled by cell division machinery

Post Your Comments:

(Date:4/17/2019)... ... April 17, 2019 , ... USDM Life Sciences (USDM) announces that Jay Crowley, ... solutions for Creating a Sustainable Global UDI Compliance Strategy at the European UDI Forum ... , What device manufacturers did to comply with the US FDA UDI ...
(Date:4/16/2019)... Texas (PRWEB) , ... April 16, 2019 , ... ... collaboration between employers and search firms with over $2 billion in placement fees ... with applicant tracking and employee onboarding platform, ExactHire. , This strategic relationship ...
(Date:4/16/2019)... (PRWEB) , ... April 16, 2019 , ... ... its featured speakers for two signature events: The 2019 ISPE Biopharmaceutical Manufacturing ... on 20–21 June. Taking place in one of the most influential bio ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... April 09, 2019 , ... USDM ... capacity of life sciences organizations to accelerate innovation and maximize productivity, announces that ... the past 12 months. , USDM’s Cloud Assurance is a managed ...
(Date:4/9/2019)... (PRWEB) , ... April 09, 2019 , ... The ... incoming members of the Society's leadership team, including a new addition to the presidential ... five of their peers to join the Society's leadership team for a three-year term ...
(Date:4/8/2019)... ... 2019 , ... US Capital Global Securities , an affiliate of US ... the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of ... sexual dysfunction disorder and is ready to begin phase 2b trials. In phase 2a ...
(Date:4/4/2019)... ... April 02, 2019 , ... Biomeme, Inc. , a ... latest field-ready solution for performing PCR, RT-PCR, qPCR, and Isothermal tests called ... Rosland Franklin, an English chemist and X-ray crystallographer who made significant contributions to ...
Breaking Biology Technology:
Cached News: